• 1. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 2. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 3. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 4. Emerging investigator series: kinetics of diopside reactivity for carbon mineralization in mafic–ultramafic rocks
  BrianaAguila,LandonHardee,H.ToddSchaef,SiavashZare,MohammadJavadAbdolhosseiniQomi,JarrodV.Crum,JadeE.HollimanJr.,ElenaTajueloRodriguez,LawrenceM.Anovitz,KevinM.Rosso,QuinR.S.Miller
• 5. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Organic sulfonic acids and derivatives Organosulfonic acids and derivatives Organosulfonic acid esters

Introduction to (2R)-2-Hydroxy-1-propyl Methanesulfonate (CAS No. 262423-81-4)

Compound with the CAS number 262423-81-4 and the product name (2R)-2-Hydroxy-1-propyl Methanesulfonate represents a significant advancement in the field of chiral chemistry and pharmaceutical research. This compound, characterized by its specific stereochemical configuration, has garnered considerable attention due to its potential applications in the development of novel therapeutic agents. The (R)-configuration at the second carbon atom, as indicated by the prefix (2R), is particularly noteworthy as it influences the compound's biological activity and interactions with biological targets.

The methanesulfonate group in the molecular structure of (2R)-2-Hydroxy-1-propyl Methanesulfonate contributes to its solubility and stability, making it a versatile intermediate in synthetic chemistry. This feature is particularly valuable in pharmaceutical synthesis, where solubility and stability are critical factors for drug formulation and delivery. Recent studies have highlighted the importance of chiral compounds in drug development, emphasizing their role in enhancing therapeutic efficacy and reducing side effects.

In recent years, there has been a surge in research focused on chiral auxiliaries and catalysts that facilitate the asymmetric synthesis of enantiomerically pure compounds. The synthesis of (2R)-2-Hydroxy-1-propyl Methanesulfonate exemplifies this trend, as it requires precise control over stereochemistry during its preparation. Advanced synthetic methodologies, including enzymatic resolution and chiral pool synthesis, have been employed to achieve high enantiomeric purity. These methods not only improve yield but also minimize environmental impact, aligning with the growing emphasis on sustainable chemistry.

The pharmacological relevance of (R)-configured compounds has been extensively studied, particularly in the context of protease inhibition and enzyme-mediated biological pathways. For instance, analogs of (2R)-2-Hydroxy-1-propyl Methanesulfonate have shown promise in inhibiting key enzymes involved in inflammation and metabolic disorders. Preliminary in vitro studies indicate that derivatives of this compound exhibit potent activity against targets such as cyclooxygenase-2 (COX-2) and lipoxygenase (LOX), which are implicated in various inflammatory conditions.

The structural motif of methanesulfonate esters provides an additional layer of functionality that can be exploited for drug design. The ester group can undergo hydrolysis or transesterification under specific conditions, allowing for further chemical modification. This flexibility makes (2R)-2-Hydroxy-1-propyl Methanesulfonate a valuable building block for medicinal chemists seeking to develop novel scaffolds with improved pharmacokinetic properties.

In clinical research, the potential of chiral compounds like (R)-configured methanesulfonates is being explored for their ability to selectively interact with biological receptors. By optimizing stereochemistry, researchers aim to enhance binding affinity and reduce off-target effects. This approach is particularly relevant in the development of central nervous system (CNS) drugs, where enantiomeric differences can significantly influence therapeutic outcomes.

The synthesis and application of (R)-configured methanesulfonates also intersect with emerging fields such as organometallic chemistry and flow chemistry. These modern techniques offer innovative ways to construct complex molecular frameworks efficiently. For example, palladium-catalyzed cross-coupling reactions have been utilized to introduce aryl or heteroaryl groups into the methanesulfonate moiety, expanding the structural diversity of these compounds.

Eco-friendly synthetic routes are increasingly being adopted to produce chiral compounds like (R)-configured methanesulfonates sustainably. Green chemistry principles emphasize minimizing waste generation, using renewable feedstocks, and employing energy-efficient processes. Recent advancements in biocatalysis have enabled the use of engineered enzymes for stereoselective transformations, reducing reliance on harsh chemical reagents.

The role of computational chemistry in designing and optimizing derivatives of (R)-configured methanesulfonates cannot be overstated. Molecular modeling techniques help predict binding interactions between these compounds and biological targets, facilitating rational drug design. High-throughput virtual screening further accelerates the identification of promising candidates for experimental validation.

The future prospects for (R)-configured methanesulfonates are bright, with ongoing research uncovering new applications across multiple therapeutic areas. As our understanding of stereochemistry deepens, so too does our ability to harness these compounds for therapeutic benefit. Collaborative efforts between academia and industry are essential to translate laboratory discoveries into clinical reality.

• 262423-83-6((2S)-2-Hydroxy-1-propyl Methanesulfonate)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)